Opinion|Videos|January 24, 2025
GOLD 2025 Report: Lung Microbiome and Chest CT Imaging in COPD
Panelists discuss how dysbiosis of the lung microbiome can exacerbate chronic obstructive pulmonary disease (COPD) through increased inflammation and altered immune responses. In contrast, chest CT imaging is indicated for patients with severe COPD, suspected comorbidities, surgical planning, or unexplained symptoms despite standard treatment. These factors highlight the complexity of COPD management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How can dysbiosis in the lung microbiome contribute to the development and progression of COPD?
- Chest CT imaging should be considered in which patient populations with COPD?
Advertisement
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Advertisement
Advertisement
Trending on HCPLive
1
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
2
Targeting the Disease Mechanism in PFIC, With Hisamitsu Hayashi, PhD
3
Residual Asthma Exacerbations on Biologics Vary by Mechanism
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5